Literature DB >> 16139172

Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN.

Jolanda Tuma1, Jan H Strubbe, Elisabeth Mocaër, Jaap M Koolhaas.   

Abstract

In rats, social defeat by an aggressive opponent induces a state of anxiety, shown by a decrease in time spent on active explorative behaviour, an increase in immobility, a clear decrease in frequency of all active behavioural parameters (enhanced passivity). We tested the hypothesis whether acute or sub-chronic agomelatine would antagonize the negative consequences of a social defeat. As many chronobiological actions of melatonin and its receptor agonist agomelatine require the integrity of the suprachiasmatic nuclei (SCN), we examined whether the anxiolytic-like action of agomelatine 1 day after a social defeat is still present in SCN-lesioned rats. Sub-chronic administration of agomelatine caused a clear reduction of the social defeat induced behavioural consequences. A single agomelatine injection prior to the post-defeat test was less effective and a single melatonin injection was hardly effective. SCN lesion did not affect the anxiety reaction after a social defeat. Thus, sub-chronic agomelatine treatment or a single agomelatine injection reduced a state of anxiety and passivity caused by asocial defeat. The defeat-induced behavioural changes do not depend on the SCN but agomelatine showed its anxiolytic action only in sham-lesioned animals, which indicates that the anxiolytic-like action of agomelatine requires the integrity of the SCN. Mechanisms sustaining this activity are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16139172     DOI: 10.1016/j.euroneuro.2005.02.004

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  20 in total

Review 1.  Circadian rhythms and mood regulation: insights from pre-clinical models.

Authors:  Colleen A McClung
Journal:  Eur Neuropsychopharmacol       Date:  2011-08-11       Impact factor: 4.600

Review 2.  Circadian genes, rhythms and the biology of mood disorders.

Authors:  Colleen A McClung
Journal:  Pharmacol Ther       Date:  2007-02-28       Impact factor: 12.310

Review 3.  Mood-related central and peripheral clocks.

Authors:  Kyle D Ketchesin; Darius Becker-Krail; Colleen A McClung
Journal:  Eur J Neurosci       Date:  2018-11-29       Impact factor: 3.386

4.  Circadian arrhythmia dysregulates emotional behaviors in aged Siberian hamsters.

Authors:  Brian J Prendergast; Kenneth G Onishi; Priyesh N Patel; Tyler J Stevenson
Journal:  Behav Brain Res       Date:  2013-12-12       Impact factor: 3.332

5.  Chronic Stress Induces Brain Region-Specific Alterations of Molecular Rhythms that Correlate with Depression-like Behavior in Mice.

Authors:  Ryan W Logan; Nicole Edgar; Andrea G Gillman; Daniel Hoffman; Xiyu Zhu; Colleen A McClung
Journal:  Biol Psychiatry       Date:  2015-02-04       Impact factor: 13.382

6.  Circadian genes Period 1 and Period 2 in the nucleus accumbens regulate anxiety-related behavior.

Authors:  Sade Spencer; Edgardo Falcon; Jaswinder Kumar; Vaishnav Krishnan; Shibani Mukherjee; Shari G Birnbaum; Colleen A McClung
Journal:  Eur J Neurosci       Date:  2012-10-08       Impact factor: 3.386

7.  Disruption of the circadian output molecule prokineticin 2 results in anxiolytic and antidepressant-like effects in mice.

Authors:  Jia-Da Li; Wang-Ping Hu; Qun-Yong Zhou
Journal:  Neuropsychopharmacology       Date:  2008-04-23       Impact factor: 7.853

Review 8.  Circadian rhythms and addiction: mechanistic insights and future directions.

Authors:  Ryan W Logan; Wilbur P Williams; Colleen A McClung
Journal:  Behav Neurosci       Date:  2014-04-14       Impact factor: 1.912

Review 9.  Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations.

Authors:  A Irem Sonmez; Ammar Almorsy; Laura B Ramsey; Jeffrey R Strawn; Paul E Croarkin
Journal:  Depress Anxiety       Date:  2020-05-17       Impact factor: 6.505

Review 10.  Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.

Authors:  Christian de Bodinat; Béatrice Guardiola-Lemaitre; Elisabeth Mocaër; Pierre Renard; Carmen Muñoz; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2010-06-25       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.